|12 Months Ended|
Dec. 31, 2016
|Segment Reporting [Abstract]|
22. Segment Information
The Company operates in three reportable segments, Dermatology Product Sales, Pharmaceutical and Biotechnology Product Development and National. The accounting policies of the Company’s segments are the same as those described in Note 2. The following tables summarize, for the periods indicated, operating results by reportable segment (table in thousands):
Corporate pre-tax loss consists of certain expenses that have not been allocated to reportable segments.
For the year ended December 31, 2016, three of the Company’s customers accounted for more than 10.0% of its total gross revenue in the amount of $ 1.9 million, $1.1 million, and $0.7 million, respectively.
At December 31, 2016, two of the Company’s customers accounted for more than 10.0% of its total accounts receivable balance in the amount of $ 1.1 million and $ 0.5 million, respectively.
Net Revenue from Pharmaceutical and Biotechnology Product Development represents collaboration revenue from TGTX in connection with Checkpoint, which is classified as related party revenue.
The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.
Reference 1: http://www.xbrl.org/2003/role/presentationRef